EGFR is a tyrosine kinase that participates in the regulation of cellular homeostasis.
Following ligand binding, EGFR stimulates downstream cell signaling cascades that …

Non‐small cell lung cancer (NSCLC) is one of the most deadly cancers worldwide, with poor
prognosis once the disease has progressed past the point at which surgery is a viable …

Background Use of cetuximab, a monoclonal antibody targeting the epidermal growth factor
receptor (EGFR), has the potential to increase survival in patients with advanced non-small …

The purpose of this article is to provide updated recommendations for the treatment of
patients with stage IV non–small-cell lung cancer. A literature search identified relevant …

Purpose To evaluate the efficacy of cetuximab plus taxane/carboplatin (TC) as first-line
treatment of advanced non–small-cell lung cancer (NSCLC). Patients and Methods This …

Background Stage IV non-small cell lung cancer (NSCLC) is a treatable, but not curable,
clinical entity in patients given the diagnosis at a time when their performance status (PS) …

The epidermal growth factor receptor (EGFR) is a receptor tyrosine kinase belonging to the
HER family of receptor tyrosine kinases. Receptor activation upon ligand binding leads to …

Abstract Treatment outcomes in advanced or metastatic non-small-cell lung cancer (NSCLC)
remain unsatisfactory, with low long-term survival rates. Palliative chemotherapy offers a …

Squamous cell carcinoma (SCC) is an epithelial malignancy involving many anatomical
sites and is the most common cancer capable of metastatic spread. Development of early …

Background This study assessed the activity of the mAb cetuximab in combination with
cisplatin and 5-fluorouracil (5-FU) in advanced esophageal squamous cell carcinoma …